Acute Promyelocytic Leukemia Unknown Status Phase 4 Trials for Cytarabine (DB00987)

Back to Acute Promyelocytic Leukemia

Also known as: Leukaemia (Acute Promyelocytic) / Promyelocytic Leukemia, Acute / Leukemia, Promyelocytic, Acute / Acute Promyelocytic Leukemia (APL) / Acute promyelocytic leukaemia / Acute promyelocytic leukemia with failed remission / Disorder: Acute promyelocytic leukemia, FAB M3 (disorder) / Acute promyelocytic leukemia (morphologic abnormality) / AML M3

Indication	Status	Phase
DBCOND0036178 (Acute Promyelocytic Leukemia)	Unknown Status	4

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01987297	Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL	Treatment	Arsenic trioxide (DB01169) Cytarabine (DB00987) Daunorubicin (DB00694) Idarubicin (DB01177) Tretinoin (DB00755)
NCT00180128	AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia	Prevention	Cytarabine (DB00987) Daunorubicin (DB00694) Idarubicin (DB01177) Mitoxantrone (DB01204)